Immuron Ltd. (IMRN) Stock Price, Financials & Summary

Price chart

Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18

Key dataSep 18, 2026

Open$1.22

From 52W high−48.09%

Volume89082.00

Market cap$9.85M

P/E (TTM)—

P/S (TTM)1.8x

Div yield—

Key dataSep 18, 2026

Open

$1.22

From 52W high

−48.09%

Volume

89082.00

Market cap

$9.85M

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−1.0x

P/E (TTM)

—

RSI (14)

44.9

MomentumView details →

1D Return

+3.39%

YTD Return

+53.70%

SummaryUpdated Jun 1, 2026

Immuron Limited (NASDAQ:IMRN) is an Australian-based biopharmaceutical company founded in 1994 that specializes in developing and commercializing polyclonal antibody therapies. The company went public on NASDAQ in 2017 and operates through two main segments: Research and Development, and Hyperimmune Products. Immuron focuses on gastrointestinal health solutions, leveraging its proprietary technology platform based on bovine colostrum with hyperimmune antibodies to create both over-the-counter products and prescription drug candidates.

Ask drillr about Immuron Ltd. →

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

—

EV/EBITDA

−1.0x

EV/Sales

0.6x

P/S (TTM)

1.8x

P/B (TTM)

1.3x

ProfitabilityView details →

Gross Margin

64.50%

Net Margin

−49.77%

EBITDA Margin

−61.39%

ROE (TTM)

−34.11%

ROA (TTM)

−28.90%

Asset Turnover

0.54x

GrowthView details →

Revenue YoY

—

EPS YoY

—

FCF YoY

—

Revenue CAGR 3Y

+61.10%

EPS CAGR 3Y

+44.44%

EBITDA YoY

—

MomentumView details →

1D Return

+3.39%

YTD Return

+53.70%

1Y Return

−38.32%

RSI (14)

44.9

vs 50D SMA

−2.16%

vs 200D SMA

+15.60%

Capital & dividendView details →

Debt/Equity

0.00x

Current Ratio

7.17x

Quick Ratio

5.90x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

−$0.17

EPS Surprise

−4529.32%

Beats (12Q)

0/12

Next Q EPS Est

—

Avg Surprise (4Q)

−2814.45%

Rev Surprise

−9.72%

Financials snapshotView financials →

Revenue (TTM)

12.63M

Net Income (TTM)

−7.96M

Op. CF (TTM)

−6.41M

Next earningsFeb 19, 2027 →

Latest newsMore news →

Immuron Limited announced it has executed an exclusive distribution agreement with Calmino group AB to launch PROIBS in the United States, following its earlier launch of PROIBS in Australia during FY2026.16d ago

Similar companies

Tevogen Bio Holdings Inc.TVGNW Senti Biosciences, Inc.SNTI Brainstorm Cell Therapeutics Inc.BCLI FibroBiologics, Inc. Common StockFBLG Aprea Therapeutics, Inc.APRE enGene Holdings Inc. WarrantsENGNW Find similar companies →

Latest newsMore news →